Health Care·Biotechnology·$5.5B
Scholar Rock Holding Company (SRRK) is a biotechnology firm focused on developing innovative therapies for serious diseases. Operating in the health care sector, the company is particularly noted for its work in muscle disorders and other conditions, which could significantly impact patient care and treatment options.
EPS
Earnings per share will provide insight into the company's profitability and cost management.
Revenue
While revenue estimates are not available, any reported figures will help gauge market demand for their therapies.
Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
0Q
EPS Beat Rate
13%
Avg EPS Surprise
-11.34%
Avg Stock Reaction
+1.24%
In Q4 2025, Scholar Rock reported an EPS of -$0.88, slightly missing estimates. The stock reacted positively the following day, gaining 1.91%.
Management Promises & Guidance
Analysts have mixed expectations for Scholar Rock's upcoming earnings, with no consensus estimates available. Investors will be closely watching for any signs of progress in their clinical trials.
Bull Case
If the company shows improved clinical trial results or unexpected revenue growth, it could lead to a strong positive reaction in the stock price.
Bear Case
Conversely, if the earnings report reveals continued losses or setbacks in drug development, it may lead to a negative market reaction.
EPS
N/AEarnings per share will provide insight into the company's profitability and cost management.
Revenue
N/AWhile revenue estimates are not available, any reported figures will help gauge market demand for their therapies.
The print will turn on these two things.
Q1
What specific progress has been made in clinical trials for their lead drug candidates?
The market will closely evaluate any updates on clinical trials as they can significantly impact future revenue and investor confidence.
Q2
Will there be any guidance on expected timelines for product launches?
Timelines for product launches are crucial for assessing the company's growth potential and market strategy.
Why consensus could be wrong
The Street may be underestimating the potential for positive trial results based on recent industry trends that favor innovative therapies.
Supporting Evidence
Recent biotech trends show increased investment and interest in muscle disorder treatments, which may benefit Scholar Rock.
The company's unique approach to drug development could yield unexpected positive results that are not currently factored into market expectations.
Key Risk
If clinical trial results exceed expectations, it could shift the market's perception and lead to a reevaluation of the company's potential.
Pre-commit to what would confirm each case.
The upcoming earnings report is critical as it will provide insights into the company's progress and future outlook, which are key for investor sentiment.
Bull Confirmed If
Positive updates on clinical trial results or a timeline for product launches could lead to a significant upward movement in stock price.
Bear Confirmed If
Any delays or negative results from clinical trials would likely confirm bearish sentiment and lead to a stock decline.
Implied Move
±N/A
There is no options market data available to gauge investor sentiment ahead of the earnings report.
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Scholar Rock beats expectations, history suggests a potential stock increase of around 1.56%, confirming a positive outlook for the company.
In-Line / Cautious
If results are in line with expectations, the stock may see a muted reaction as investors await further clarity on future plans.
Miss
Should the company miss expectations, history suggests a potential decline of about 1.56%, which could raise concerns about the company's trajectory.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
PARAMOUNT SKYDANCE C Class B
May 4, 2026